MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories (NASDAQ:MLAB) has announced a quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2025, to shareholders of record as of August 29, 2025.
Mesa Labs is a global leader specializing in life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. Their products and services help ensure product integrity, enhance patient and worker safety, and improve quality of life worldwide.
Mesa Laboratories (NASDAQ:MLAB) ha annunciato un dividendo trimestrale di 0,16 $ per azione di azioni ordinarie. Il dividendo sarà corrisposto il 15 settembre 2025 agli azionisti registrati al 29 agosto 2025.
Mesa Labs è un leader globale specializzato in strumenti per le scienze della vita e soluzioni critiche di controllo qualità per applicazioni regolamentate nei settori farmaceutico, sanitario e dei dispositivi medici. I loro prodotti e servizi contribuiscono a garantire l'integrità del prodotto, migliorare la sicurezza di pazienti e lavoratori e aumentare la qualità della vita a livello mondiale.
Mesa Laboratories (NASDAQ:MLAB) ha anunciado un dividendo trimestral de 0,16 $ por acción de acciones comunes. El dividendo se pagará el 15 de septiembre de 2025 a los accionistas registrados al 29 de agosto de 2025.
Mesa Labs es un líder global especializado en herramientas para ciencias de la vida y soluciones críticas de control de calidad para aplicaciones reguladas en las industrias farmacéutica, sanitaria y de dispositivos médicos. Sus productos y servicios ayudan a garantizar la integridad del producto, mejorar la seguridad de pacientes y trabajadores y elevar la calidad de vida en todo el mundo.
Mesa Laboratories (NASDAQ:MLAB)는 보통주 1주당 0.16달러의 분기 배당금을 발표했습니다. 배당금은 2025년 9월 15일에 지급되며, 2025년 8월 29일 기준 주주에게 지급됩니다.
Mesa Labs는 제약, 의료 및 의료기기 산업의 규제된 응용 분야를 위한 생명과학 도구 및 핵심 품질 관리 솔루션을 전문으로 하는 글로벌 선도 기업입니다. 이들의 제품과 서비스는 제품 무결성을 보장하고, 환자와 근로자의 안전을 강화하며, 전 세계적으로 삶의 질을 향상시키는 데 기여합니다.
Mesa Laboratories (NASDAQ:MLAB) a annoncé un dividende trimestriel de 0,16 $ par action d’actions ordinaires. Le dividende sera versé le 15 septembre 2025 aux actionnaires inscrits au 29 août 2025.
Mesa Labs est un leader mondial spécialisé dans les outils scientifiques de la vie et les solutions critiques de contrôle qualité pour les applications réglementées dans les industries pharmaceutique, de la santé et des dispositifs médicaux. Leurs produits et services contribuent à garantir l’intégrité des produits, à améliorer la sécurité des patients et des travailleurs, et à accroître la qualité de vie dans le monde entier.
Mesa Laboratories (NASDAQ:MLAB) hat eine vierteljährliche Dividende von 0,16 $ pro Aktie der Stammaktien angekündigt. Die Dividende wird am 15. September 2025 an die zum 29. August 2025 eingetragenen Aktionäre ausgezahlt.
Mesa Labs ist ein weltweit führendes Unternehmen, das sich auf Werkzeuge für die Lebenswissenschaften und kritische Qualitätskontrolllösungen für regulierte Anwendungen in der Pharma-, Gesundheits- und Medizinprodukteindustrie spezialisiert hat. Ihre Produkte und Dienstleistungen tragen dazu bei, die Produktintegrität zu gewährleisten, die Sicherheit von Patienten und Mitarbeitern zu erhöhen und die Lebensqualität weltweit zu verbessern.
- Regular quarterly dividend maintained at $0.16 per share
- Demonstrates commitment to returning value to shareholders
- Company maintains strong market position in life science tools and quality control solutions
- Dividend amount remains unchanged, showing no growth
- Operating in highly regulated industries with significant compliance requirements
LAKEWOOD, Colo., July 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of
About Mesa Laboratories, Inc.
Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.
Forward Looking Statements
This press release may contain information that constitutes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. Forward-looking statements include statements relating to revenues and growth, operating results, profit margin pressure, industry conditions, economic conditions, demand, competition, the effects of additional actions taken to become more efficient or lower costs, risks related to the integration of acquired businesses, changes in legal and regulatory matters, the ability to generate additional cash flow, and any events or developments that we expect or anticipate will occur in the future. Generally, the words “expect,” “anticipate,” “seek,” “intend,” “plan,” “believe,” “could,” “estimate,” “may,” “target,” “project,” and similar expressions identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These statements are based upon current information and expectations. Actual results may differ materially from those estimated or anticipated as a result of these risks and unknowns or other risks and uncertainties. For additional information concerning these and other risks and uncertainties that could affect these statements, and our business, see our Annual Report on Form 10-K for the year ended March 31, 2025, as well as other risks and uncertainties detailed from time to time in our reports on Forms 10-Q and 8-K subsequently filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof, to provide any updates, or to reflect the occurrence of future events.
CONTACT: Gary Owens; President and CEO, or John Sakys; CFO, both of Mesa Laboratories, Inc., +1-303-987-8000
For more information about the Company, please visit its website at www.mesalabs.com
FAQ
When will Mesa Labs (MLAB) pay its next dividend?
What is Mesa Labs' (MLAB) current dividend yield?
What industries does Mesa Laboratories (MLAB) serve?
Who is eligible for Mesa Labs' Q3 2025 dividend?
